Strategy and thinking of differentiating autoimmune pancreatitis from pancreatic ductal adenocarcinoma

doi:10.3877/cma.j.issn.2095-3232.2024.02.001

Abstract

Abstract:

Autoimmune pancreatitis (AIP) is a special type of pancreatitis, which primarily manifests as painless obstructive jaundice, mild abdominal pain or acute pancreatitis. In clinical practice, it is constantly misdiagnosed with pancreatic ductal adenocarcinoma (PDAC), whereas treatment and prognosis of these two conditions are completely different. Prior to surgery, it is difficult to make a definite differential diagnosis. In this article, the differences between them were illustrated from clinical manifestations, imaging, serological and histopathological characteristics, and relevant challenging problems were discussed accordingly.

Key words: Autoimmune pancreatitis, Pancreatic ductal adenocarcinoma, Differential diagnosis

Rui Bai, Bei Sun. Strategy and thinking of differentiating autoimmune pancreatitis from pancreatic ductal adenocarcinoma[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(02): 121-126.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2024.02.001

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2024/V13/I02/121

References 41

[1]	Sarles H, Sarles JC, Muratore R, et al. Chronic inflammatory sclerosis of the pancreas—an autonomous pancreatic disease?[J]. Am J Dig Dis, 1961(6):688-698.
[2]	Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. proposal of the concept of autoimmune pancreatitis[J]. Dig Dis Sci, 1995, 40(7):1561-1568.
[3]	Qureshi A, Ghobrial Y, de Castro J, et al. Autoimmune pancreatitis- what we know and what do we have to know?[J]. Autoimmun Rev, 2021, 20(10):102912.
[4]	Mack S, Flattet Y, Bichard P, et al. Recent advances in the management of autoimmune pancreatitis in the era of artificial intelligence[J]. World J Gastroenterol, 2022, 28(48):6867-6874.
[5]	Blaho M, Dítě P, Kunovský L, et al. Autoimmune pancreatitis-an ongoing challenge[J]. Adv Med Sci, 2020, 65(2):403-408.
[6]	Lee SC, Yang CH, Chang CT, et al. Diagnostic utility of serum IgG4 in autoimmune pancreatitis: an updated comprehensive systematic review and meta-analysis[J]. J Clin Gastroenterol, 2022, 56(9):810-817.
[7]	van Heerde MJ, Buijs J, Hansen BE, et al. Serum level of Ca19-9 increases ability of IgG4 test to distinguish patients with autoimmune pancreatitis from those with pancreatic carcinoma[J]. Dig Dis Sci, 2014, 59(6):1322-1329.
[8]	Chen S, Zhang H, Fang F, et al. Characteristics of mass-forming autoimmune pancreatitis commonly misdiagnosed as a malignant tumor[J]. Front Surg, 2023(10):1017621.
[9]	Minaga K, Watanabe T, Hara A, et al. Identification of serum IFN-α and IL-33 as novel biomarkers for type 1 autoimmune pancreatitis and IgG4-related disease[J]. Sci Rep, 2020, 10(1):14879.
[10]	Hubers LM, Vos H, Schuurman AR, et al. Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease[J]. Gut, 2018, 67(4):728-735.
[11]	Shiokawa M, Kodama Y, Sekiguchi K, et al. Laminin 511 is a target antigen in autoimmune pancreatitis[J]. Sci Transl Med, 2018, 10(453):eaaq0997.
[12]	Perugino CA, AlSalem SB, Mattoo H, et al. Identification of galectin-3 as an autoantigen in patients with IgG4-related disease[J]. J Allergy Clin Immunol, 2019, 143(2):736-745.e6.
[13]	Akamatsu M, Makino N, Ikeda Y, et al. Specific MAPK-associated microRNAs in serum differentiate pancreatic cancer from autoimmune pancreatitis[J]. PLoS One, 2016, 11(7):e0158669.
[14]	Li J, Liu F, Fang X, et al. CT radiomics features in differentiation of focal-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma: a propensity score analysis[J]. Acad Radiol, 2022, 29(3):358-366.
[15]	Wolske KM, Ponnatapura J, Kolokythas O, et al. Chronic pancreatitis or pancreatic tumor? a problem-solving approach[J]. Radiographics, 2019, 39(7):1965-1982.
[16]	Park S, Chu LC, Hruban RH, et al. Differentiating autoimmune pancreatitis from pancreatic ductal adenocarcinoma with CT radiomics features[J]. Diagn Interv Imaging, 2020, 101(9):555-564.
[17]	Ha J, Choi SH, Kim KW, et al. MRI features for differentiation of autoimmune pancreatitis from pancreatic ductal adenocarcinoma: a systematic review and meta-analysis[J]. Dig Liver Dis, 2022, 54(7):849-856.
[18]	Yoon SB, Jeon TY, Moon SH, et al. Systematic review and meta-analysis of MRI features for differentiating autoimmune pancreatitis from pancreatic adenocarcinoma[J]. Eur Radiol, 2022, 32(10):6691-6701.
[19]	Kim HJ, Kim YK, Jeong WK, et al. Pancreatic duct "Icicle sign" on MRI for distinguishing autoimmune pancreatitis from pancreatic ductal adenocarcinoma in the proximal pancreas[J]. Eur Radiol, 2015, 25(6):1551-1560.
[20]	Moon SH, Yoon SB, Jeon TY. ADC values from diffusion-weighted imaging may be lower for autoimmune pancreatitis than for pancreatic ductal adenocarcinoma[J]. Dig Liver Dis, 2022, 54(7):992-993.
[21]	Sekito T, Ishii Y, Serikawa M, et al. The role of apparent diffusion coefficient value in the diagnosis of localized type 1 autoimmune pancreatitis: differentiation from pancreatic ductal adenocarcinoma and evaluation of response to steroids[J]. Abdom Radiol, 2021, 46(5):2014-2024.
[22]	Qiu YJ, Zhao GC, Shi SN, et al. Application of dynamic contrast enhanced ultrasound in distinguishing focal-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma[J]. Clin Hemorheol Microcirc, 2022, 81(2):149-161.
[23]	Bandini G, Moggi Pignone A, Mastrangelo L, et al. Autoimmune pancreatitis: can we truly recognize it? usefulness of contrast-enhanced ultrasonography in two different cases[J]. Eur J Gastroenterol Hepatol, 2022, 34(8):885-886.
[24]	Suzuki H, Ishikawa T, Ohno E, et al. An initial trial of quantitative evaluation of autoimmune pancreatitis using shear wave elastography and shear wave dispersion in transabdominal ultrasound[J]. Pancreatology, 2021, 21(4):682-687.
[25]	Ohtani M, Ofuji K, Akazawa Y, et al. Clinical usefulness of [18F]-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography for distinguishing between autoimmune pancreatitis and pancreatic cancer[J]. Pancreas, 2021, 50(7):1014-1019.
[26]	Cheng MF, Guo YL, Yen RF, et al. Clinical utility of FDG PET/CT in patients with autoimmune pancreatitis: a case-control study[J]. Sci Rep, 2018, 8(1):3651.
[27]	Wei W, Jia G, Wu Z, et al. A multidomain fusion model of radiomics and deep learning to discriminate between PDAC and AIP based on ¹⁸F-FDG PET/CT images[J]. Jpn J Radiol, 2023, 41(4):417-427.
[28]	Tacelli M, Zaccari P, Petrone MC, et al. Differential EUS findings in focal type 1 autoimmune pancreatitis and pancreatic cancer: a proof-of-concept study[J]. Endosc Ultrasound, 2022, 11(3):216-222.
[29]	Ishikawa T, Kawashima H, Ohno E, et al. Usefulness of endoscopic ultrasound-guided fine-needle biopsy for the diagnosis of autoimmune pancreatitis using a 22-gauge Franseen needle: a prospective multicenter study[J]. Endoscopy, 2020, 52(11):978-985.
[30]	Lisotti A, Frazzoni L, Fuccio L, et al. Repeat EUS-FNA of pancreatic masses after nondiagnostic or inconclusive results: systematic review and meta-analysis[J]. Gastrointest Endosc, 2020, 91(6):1234-1241, e4.
[31]	Yoon SB, Moon SH, Song TJ, et al. Endoscopic ultrasound-guided fine needle aspiration versus biopsy for diagnosis of autoimmune pancreatitis: systematic review and comparative meta-analysis[J]. Dig Endosc, 2021, 33(7):1024-1033.
[32]	Chhoda A, Rustagi T. EUS-guided needle biopsy for autoimmune pancreatitis[J]. Clin J Gastroenterol, 2020, 13(5):669-677.
[33]	Gkolfakis P, Crinò SF, Tziatzios G, et al. Comparative diagnostic performance of end-cutting fine-needle biopsy needles for EUS tissue sampling of solid pancreatic masses: a network meta-analysis[J]. Gastrointest Endosc, 2022, 95(6):1067-1077. e15.
[34]	Löhr JM, Vujasinovic M, Rosendahl J, et al. IgG4-related diseases of the digestive tract[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(3):185-197.
[35]	Liu B, Tang N, Yao Y, et al. Steroid treatment response combined with serological mark in differentiating type-1 autoimmune pancreatitis from pancreatic cancer[J]. Medicine, 2022, 101(45):e31660.
[36]	Mitamura K, Arai-Okuda H, Yamamoto Y, et al. Disease activity and response to therapy monitored by [¹⁸F]FDG PET/CT using volume-based indices in IgG4-related disease[J]. EJNMMI Res, 2020, 10(1):153.
[37]	Shiokawa M, Kodama Y, Yoshimura K, et al. Risk of cancer in patients with autoimmune pancreatitis[J]. Am J Gastroenterol, 2013, 108(4):610-617.
[38]	Macinga P, Pulkertova A, Bajer L, et al. Simultaneous occurrence of autoimmune pancreatitis and pancreatic cancer in patients resected for focal pancreatic mass[J]. World J Gastroenterol, 2017, 23(12):2185-2193.
[39]	Majumder S, Mohapatra S, Lennon RJ, et al. Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary immunoglobulin G4-related disease[J]. Clin Gastroenterol Hepatol, 2018, 16(12):1947-1953.
[40]	Sano T, Kikuta K, Takikawa T, et al. The M-ANNHEIM-AiP-Activity-Score is useful for predicting relapse in patients with type 1 autoimmune pancreatitis[J]. Pancreatology, 2023, 23(1):112-119.
[41]	Kubota K, Kamisawa T, Nakazawa T, et al. Reducing relapse through maintenance steroid treatment can decrease the cancer risk in patients with IgG4-sclerosing cholangitis: based on a Japanese nationwide study[J]. J Gastroenterol Hepatol, 2023, 38(4):556-564.

Please choose a citation manager

Content to export